Related Experiment Video
Updated: Jan 30, 2026

High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts
Published on: December 20, 2024
Targeted neoadjuvant therapy in the HER-2-positive breast cancer patients: a systematic review and meta-analysis
Wenhua Ma1, Fugang Zhao2, Changpeng Zhou1
1Department of Oncology, The First Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China.
Aim:
To evaluate efficacy and safety of lapatinib or trastuzumab alone or both plus chemotherapy for the treatment of breast cancer patients with positive HER-2 expression.
Methods:
Cochrane Central Register of Controlled Trials, PubMed, MEDLINE, OVID, Embase, Chinese Biomedical Literature Database, and China Academic Journals Database were searched from 1994 through December 2017 using the keywords "breast cancer", "preoperative", "neo-adjuvant", "lapatinib", "pertuzumab", "Herceptin", and "trastuzumab".
Results:
Meta-analysis found that pathological complete response (PCR; risk ratio [RR]=0.82, 95% CI: 0.72-0.93) and tall PCR (tPCR; RR=0.77, 95% CI: 0.67-0.88) of chemotherapy plus lapatinib were significantly less effective or safe compared to that of chemotherapy plus trastuzumab (P<0.05). PCR (RR=1.30, 95% CI: 1.15-1.47) and tPCR (RR=1.32, 95% CI: 1.16-1.50) of chemotherapy plus both lapatinib and trastuzumab were significantly superior to that of chemotherapy plus trastuzumab alone (P<0.05). However, there was no significant difference in breast reservation rate between chemotherapy plus lapatinib vs chemotherapy plus trastuzumab (RR=0.91, 95% CI: 0.72-1.16) or chemotherapy plus both lapatinib and trastuzumab (RR=1.11, 95% CI: 0.73-1.68, P>0.05). Incidence of diarrhea, hepatic toxicity, and skin rash in the groups of chemotherapy plus lapatinib or chemotherapy plus both lapatinib and trastuzumab was significantly higher than that in chemotherapy plus trastuzumab (P<0.05).
Conclusion:
Efficacy of lapatinib was less than that of trastuzumab, but incidence of adverse effect of lapatinib was higher than that of trastuzumab. Combination of chemotherapy plus both lapatinib and trastuzumab could significantly increase PCR and tPCR in breast cancer patients, but rate of breast conservation, event-free survival, and overall survival was not significantly improved. Incidence of diarrhea, hepatic toxicity, and skin rash was significantly increased in the groups using lapatinib.
Insights
Lapatinib showed less efficacy and more adverse effects than trastuzumab in HER-2 positive breast cancer. Combining both drugs with chemotherapy improved pathological complete response but did not significantly enhance survival rates.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- HER-2 positive breast cancer requires targeted therapies.
- Lapatinib and trastuzumab are HER-2 targeted agents.
- Chemotherapy is a standard treatment for breast cancer.
Purpose of the Study:
- To compare the efficacy and safety of lapatinib versus trastuzumab, both alone and in combination with chemotherapy.
- To evaluate these treatments in HER-2 positive breast cancer patients undergoing neoadjuvant therapy.
Main Methods:
- A systematic literature search was conducted across multiple databases.
- Keywords included "breast cancer", "preoperative", "neo-adjuvant", "lapatinib", and "trastuzumab".
- Meta-analysis was used to synthesize data from controlled trials up to December 2017.
Main Results:
- Chemotherapy plus lapatinib was less effective and safe than chemotherapy plus trastuzumab regarding pathological complete response (PCR) and tall PCR (tPCR).
- Combining chemotherapy with both lapatinib and trastuzumab significantly improved PCR and tPCR compared to trastuzumab alone.
- Increased incidence of diarrhea, hepatic toxicity, and skin rash was observed with lapatinib-containing regimens.
Conclusions:
- Lapatinib demonstrated lower efficacy and higher adverse event rates than trastuzumab.
- The combination of chemotherapy with both lapatinib and trastuzumab enhanced PCR and tPCR but did not significantly improve survival outcomes.
- Lapatinib-containing regimens were associated with increased gastrointestinal and dermatological toxicities.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
meta-Directing Deactivators: –NO2, –CN, –CHO, –⁠CO2R, –COR, –CO2H
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Random and Systematic Errors

